Parsity Group successfully appoints Brendan O’Grady as CEO Formulations Business for Glenmark Pharmaceuticals.
Parsity Group are pleased to announce their successful partnership with Glenmark Pharmaceuticals to secure Brendan O’Grady as CEO Global Formulations Business, effective 13th June 2022. This follows on from Glenmark Pharmaceuticals recently announced expansion of its leadership team with the appointment of Christoph Stoller in November 2021 as its President and Business Head Europe, a search also delivered by Parsity Group.
A mandated global executive search was undertaken by Parsity Group in preparation for what is set to be a transformative period for Glenmark Pharmaceuticals. An experienced and highly regarded pharma leader, Brendan O’Grady, arrives from Amwell where he was Chief Growth & Commercial Officer. He was previously with Teva Pharmaceuticals for over 20 years where he was most recently President & CEO, Teva USA and EVP North America Commercial. At Glenmark Pharmaceuticals he will spearhead the continued expansion of the company’s operations in globally.
Having started on 13th June, Mr O’Grady brings an extensive and relevant track record within the pharmaceutical sector going back over 30 years, which will prove invaluable as Glenmark Pharmaceuticals ramps up its growth from both a portfolio and geographical perspective.
Brendan O’Grady commented:
"The team at Parsity Group is deeply engaged in understanding its customer’s needs and have very good connections within the global generics and speciality pharmaceuticals industry. The executive search process was conducted in an open, friendly and professional manner. The communications were frequent, so I was always informed on the status of the project. Very enjoyable experience. I would certainly work with Parsity Group again."